| Pharmaceutical R&D and Drug Development | Discovery, clinical development of new chemical entities, antibody-drug conjugates, and novel drug delivery systems in oncology and immunology. | Strong IP portfolio, early-stage clinical assets with orphan drug designations, exclusive licensing agreements, and specialized scientific expertise. | B2B model with pharmaceutical companies, specialty pharma partners, and global healthcare providers. | Licensed ophthalmic drugs and proprietary ADCs; early clinical assets with high-value potential. | 72 | 100 | License fees, milestone payments, royalties from partnered products, and potential product commercialization. | Royalty-based, milestone-driven licensing agreements, and potential direct product sales in future. | Advancement of clinical pipeline, regulatory approvals, strategic partnerships, and cost structure optimization. | SCD-153, SBO-154, Xelpros |
